



Date: 06-10-2023

**The General Manager
Bombay Stock Exchange Limited
Listing Compliance
Department of Corporate Services - CRD
BSE, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001**

Ref: - Scrip Code/ SYMBOL: 526139

Dear Sir / Madam,

Subject: Intimation of non-applicability of Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended on 30th September 2023

Pursuant to SEBI circular-CIR/CFD/CMD1/162/2019 dated 24th December, 2019 and as amended from time to time, a listed entity shall submit a Statement of Deviation or Variation for proceeds of public issue / rights issue preferential issue, Qualified Institutions Placement (QIP) etc.

It is to be noted that, during the reporting quarter ended on 30th September 2023, there was no public issue, rights' issue, preferential issue etc.

Hence, the Statement of Deviation or Variation in Public Issue, Rights Issue, Preferential Issue etc. under Regulation 32(1) of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 for the quarter ended 30th September 2023 is not applicable to the Company.

Please note that we are unable to file under XBRL mode as the form is not allowing NIL entry.

Kindly take the above intimation on your record and oblige.

Thanking you

Yours Sincerely

For TRANSGENE BIOTEK LIMITED

**DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR**